Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 & CD20 Bispecific CAR T Cells in Relapsed/Refractory B Cell Hematological Tumors
NCT06503094Phase 2Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) in B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Lymphoplasmacytic Lymphoma (LPL). Started Jan 2024; status: recruiting.
02
Drugs
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital)
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)chronic lymphocytic leukemia (CLL)follicular lymphoma (FL)marginal zone lymphoma (MZL)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on NCT06503094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503094.